Nothing Special   »   [go: up one dir, main page]

Biberstine-Kinkade, 1997 - Google Patents

Soluble peptidoglycan fragments released by Neisseria Gonorrhoeae suppress appetite

Biberstine-Kinkade, 1997

Document ID
7167181599102352660
Author
Biberstine-Kinkade K
Publication year

External Links

Snippet

The underlying hypothesis for this dissertation is that soluble, physiologically realistic, peptidoglycan (PG) fragments decrease appetite in rats. One goal is to identify what types of PG fragments might actually gain access to host tissue upon release from bacteria …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)

Similar Documents

Publication Publication Date Title
US8703146B2 (en) Toll-like receptor 5 ligands and methods of use
Malaviya et al. Mast cell modulation of immune responses to bacteria
Aleljung et al. Purification of collagen-binding proteins of Lactobacillus reuteri NCIB 11951
US5089274A (en) Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
Phalipon et al. Shigella’s ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?
US20030044429A1 (en) Toll-like receptor 5 ligands and methods of use
Nagao et al. Inhibition of macrophage migration by muramyl peptides
Griffin et al. Translation of peptidoglycan metabolites into immunotherapeutics
JPH09508359A (en) Anti-gram positive bacteriological methods and substances
KR20050109928A (en) Anti-inflammatory activity from lactic acid bacteria
WO2007001332A2 (en) Anti-pathogen immunoadhesins
JP2002541066A (en) Antimicrobial / Endotoxin neutralizing polypeptide
Fujimoto et al. Peptidoglycan as Nod1 ligand; fragment structures in the environment, chemical synthesis, and their innate immunostimulation
EP3061766B1 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
JPH11510793A (en) Intranasal vaccination for gastrointestinal disease
JP3558347B2 (en) Alpha B crystallin for use in the diagnosis and treatment of autoimmune diseases, especially multiple sclerosis
JP3163171B2 (en) IgA production promoter
Biberstine-Kinkade Soluble peptidoglycan fragments released by Neisseria Gonorrhoeae suppress appetite
Wilder Proinflammatory microbial products as etiologic agents of inflammatory arthritis
JP4149713B2 (en) Infectious disease treatment
JP4476934B2 (en) Novel peptide and immunostimulant, functional food and method for producing functional food
Lamont et al. Recent Advances in Clostridium difficile and its Toxins: Report of a Workshop held at Tours, France, 4 May, 1995
KHANSARI et al. A thymosin–tuftsin conjugate as a new potential immunomodulator in cattle
Chu Immunomodulation by Shiga toxin 2
Fleming Induction of arthritis by gonococcal peptidoglycan fragments